|
Mechanism5-HT3 receptor antagonists [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given With Ondansetron to Subjects With Anti-AchR Positive Myasthenia Gravis
This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.
100 Clinical Results associated with DAS-MG, Inc
0 Patents (Medical) associated with DAS-MG, Inc
100 Deals associated with DAS-MG, Inc
100 Translational Medicine associated with DAS-MG, Inc